CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

NewsGuard 100/100 Score

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.

The findings show precisely how a key part of the antibody, called the antigen binding fragment, or Fab, attaches to two adjacent protein molecules that make up the virus's outer shell. This "crosslinking" attachment between molecules is repeated over the entire shell, interlocking the 30 molecular "rafts" that make up the shell and preventing structural changes needed for the virus to infect host cells, said Michael Rossmann, the Hanley Distinguished Professor of Biological Sciences in Purdue's College of Science.

"The antibody crosslinking causes the virus to become rigid, and this rigidity prevents conformational changes to the virus needed to fuse with host cells," Rossmann said.

Findings are detailed in a research paper that appeared in October in Proceedings of the National Academy of Sciences. The team included postdoctoral researcher B-rbel Kaufmann, other researchers at Purdue, the Washington University School of Medicine in St. Louis and the biotechnology company Crucell Holland B.V. in The Netherlands.

Learning how antibodies neutralize viruses is important for developing effective vaccines, Rossmann said.

"There are many antibodies that can neutralize West Nile virus," he said. "These findings concern a specific antibody, called CR4354. It uses an unusual approach to neutralize the virus. Normally an antibody binds to a single molecule, but now we see this crosslinking, which is quite clever because it ties everything rigidly together."

The researchers used a process called cryoelectron microscopy to take detailed pictures of the Fab-virus complex. They also used X-ray crystallography to learn the antibody's precise crystalline structure.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression